The U.S. Biomedical Advanced Research and
Development Authority (BARDA) has exercised its option under a 2018
contract to provide an additional $15.9M of funding to Spero
Therapeutics (SPRO -2.1%)
to support the development of tebipenem HBr for the treatment of
complicated urinary tract infections (cUTI), a Fast Track- and Qualified
Infectious Disease Product-tagged indication in the U.S.
A Phase 3 study, ADAPT-PO, is ongoing with topline data expected in Q3.
Tebipenem HBr (tebipenem pivoxil hydrobromide;
formerly SPR994) is an oral carbapenem antibiotic marketed in Japan by
Meiji Seika Pharma Co., Ltd. for infections related to pneumonia, otitis
media (ear infection) and sinusitis in children.
https://seekingalpha.com/news/3538623-barda-oks-additional-funding-for-development-of-spero-antibiotic
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.